Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 09/30/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 184.83% | 184.83% | 94.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 184.83% | 184.83% | 94.70% |
| Cost of Revenue | -- | -- | 269.25% | 269.25% | 251.64% |
| Gross Profit | -- | -- | 76.19% | 76.19% | -79.22% |
| SG&A Expenses | -- | -- | -23.15% | -23.15% | 6.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -15.74% | -15.74% | 13.50% |
| Operating Income | -- | -- | 25.18% | 25.18% | -9.16% |
| Income Before Tax | -- | -- | 141.23% | 141.23% | 168.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 141.23% | 141.23% | 168.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 141.23% | 141.23% | 168.44% |
| EBIT | -- | -- | 25.18% | 25.18% | -9.16% |
| EBITDA | -- | -- | 25.96% | 25.96% | -8.47% |
| EPS Basic | -- | -- | 140.00% | 140.00% | 166.67% |
| Normalized Basic EPS | -- | -- | 135.29% | 135.29% | 165.52% |
| EPS Diluted | -- | -- | 112.82% | 112.82% | 130.61% |
| Normalized Diluted EPS | -- | -- | 117.39% | 117.39% | 138.71% |
| Average Basic Shares Outstanding | -- | -- | 4.37% | 4.37% | 5.71% |
| Average Diluted Shares Outstanding | -- | -- | 16.93% | 16.93% | 8.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |